Disappointing phase I results halt Novo's Dutch acquisition

Novo Nordisk has chosen not to acquire its collaboration partner from the Netherlands after disappointing phase I results for a potential drug for cardiovascular diseases were reported.
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen

Dutch company Staten Biotechnology retains its independence as Novo Nordisk has decided not to exercise an option to acquire both the company and its lead candidate, STT-5058, the Danish pharmaceutical company reports in its financial report on Wednesday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading